Background Glioblastoma (GBM), a highly malignant brain tumor, invariably recurs after
therapy. Quiescent GBM cells represent a potential source of tumor recurrence, but little is …

Glioblastoma (GBM), an incurable tumor, remains difficult to model and more importantly to
treat due to its genetic/epigenetic heterogeneity and plasticity across cellular states. The …

Background Despite extensive molecular characterization, we lack a comprehensive
understanding of lineage identity, differentiation, and proliferation in high-grade gliomas …

Glioblastoma (GBM) is an incurable and highly heterogeneous brain tumor, originating from
human neural stem/progenitor cells (hNSCs/hNPCs) years ahead of diagnosis. Despite …

Glioblastoma (GBM) is the most lethal primary brain tumor characterized by significant
cellular heterogeneity, namely tumor cells, including GBM stem-like cells (GSCs) and …

Background. Molecular profile of glioblastoma multiforme (GBM) revealed 4 subtypes, 2 of
which, proneural and mesenchymal, have been predominantly observed, with the latter …

The histopathological and molecular heterogeneity of glioblastomas represents a major
obstacle for effective therapies. Glioblastomas do not develop autonomously, but evolve in a …

Glioblastoma (GBM) is the most common and aggressive primary brain tumor, in which GBM
stem cells (GSCs) were identified to contribute to aggressive phenotypes and poor …

Glioblastoma multiforme (GBM) is the most deadly brain tumor, and currently lacks effective
treatment options. Brain tumor-initiating cells (BTICs) and orthotopic xenografts are widely …

Simple Summary Glioblastoma stem-like cells (GSCs) drive the progression and therapeutic
resistance of glioblastoma. GSC plasticity allows them to adapt to different …